Literature DB >> 9121412

[Preventive antimycotic therapy of neutropenic and immunosuppressed patients].

M Ruhnke1, J Beyer.   

Abstract

Fungal infections are of increasing importance in severely neutropenic and immunosuppressed patients because of their high incidence and their high mortality once systemic dissemination has occurred. Various prophylactic strategies have been developed that include environmental measures as well as topical and systemic antimycotic prophylaxis. In this review the causative pathogens and patients at risk for developing fungal infections will be identified. Specific strategies will be discussed for each patient population and suggestions made for areas of future research.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9121412     DOI: 10.1007/bf03042279

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  73 in total

Review 1.  Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. Working party of the British Society for Antimicrobial Chemotherapy.

Authors: 
Journal:  J Antimicrob Chemother       Date:  1993-07       Impact factor: 5.790

2.  Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study.

Authors:  C L Leen; E M Dunbar; M E Ellis; B K Mandal
Journal:  J Infect       Date:  1990-07       Impact factor: 6.072

3.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

Authors:  J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

Review 4.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

5.  Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group.

Authors:  J N Philpott-Howard; J J Wade; G J Mufti; K W Brammer; G Ehninger
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

6.  An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis.

Authors:  J E Karp; P A Burch; W G Merz
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

7.  Fungal infections in cancer patients: an international autopsy survey.

Authors:  G Bodey; B Bueltmann; W Duguid; D Gibbs; H Hanak; M Hotchi; G Mall; P Martino; F Meunier; S Milliken
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

8.  Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome.

Authors:  V A Morrison; R J Haake; D J Weisdorf
Journal:  Am J Med       Date:  1994-06       Impact factor: 4.965

9.  Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia.

Authors:  B Hertenstein; W V Kern; T Schmeiser; M Stefanic; D Bunjes; M Wiesneth; J Novotny; H Heimpel; R Arnold
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

10.  Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily.

Authors:  D A Stevens; S I Greene; O S Lang
Journal:  Arch Intern Med       Date:  1991-12
View more
  1 in total

Review 1.  [Febrile neutropenia: practical aspects].

Authors:  P Harten; B Seyfarth; N Schmitz
Journal:  Med Klin (Munich)       Date:  1998-10-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.